SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2022 - (NASDAQ: SPRO)

NEW YORK, July 20, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Spero Therapeutics, Inc..

Shareholders who purchased shares of SPRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29971&from=4

CLASS PERIOD: May 6, 2021 to May 2, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: July 25, 2022 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/spero-therapeutics-inc-loss-submission-form/?id=29971&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPRO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is July 25, 2022. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [e-mail]
Phone: [phone]

View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-spero-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-july-25-2022--nasdaq-spro-301589564.html

SOURCE The Gross Law Firm

Copyright 2022 PR Newswire